News | PET-CT | June 08, 2015

Steinberg Diagnostic Medical Imaging Installs First Toshiba Celesteion PET/CT in the U.S.

Wide-bore system emphasizes comfort for all patient types with high-quality images

Toshiba, Celesteion, Steinberg Diagnostic Medical Imaging, U.S., first

June 8, 2015 - Steinberg Diagnostic Medical Imaging (SDMI) of Las Vegas has bolstered its capabilities by installing the United States' first Celesteion PET/CT system from Toshiba America Medical Systems Inc. The Celesteion allows SDMI to provide the highest quality PET/CT (positron emission tomography/computed tomography) images and exams without sacrificing patient comfort.

"With the Celesteion, we found a wide-bore system that let us scan a variety of patients comfortably, as well as being a more-than-capable planning device for both PET and CT radiation therapy," said Mark Winkler, M.D., professor of health sciences at the University of Nevada, Las Vegas and founding partner of SDMI. "It's become the preferred system among our patients, as well as giving us the long term outlook of more referrals with the increase in oncological offerings."

The Celesteion is designed with the patient in mind, with features that include:

  • 90 cm CT bore and 88 cm PET bore – Offering a feeling of openness and versatile patient positioning;
  • Fast and accurate diagnoses – Accurate lesion detection with time of flight technology and a 70 cm PET and CT field-of-view;
  • System versatility – The Celesteion can perform diagnostic CT imaging, CT interventions, PET/CT imaging and CT radiation oncology simulation scans; and
  • CT dose reduction – Ensuring patient safety is not a choice, Celesteion comes standard with Toshiba's most advanced CT dose reduction technology, AIDR 3D, and conforms to the requirements of MITA's XR-29 Smart Dose Standard

 

For more information: www.medical.toshiba.com

Related Content

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topic at the conference.

Feature | Nuclear Imaging | November 22, 2019 | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September...
Videos | Nuclear Imaging | November 07, 2019
American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac...
Videos | Nuclear Imaging | November 06, 2019
Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at...
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. The image shows how SPECT allows the reader to distinguish between blood pool activity and radiotracer uptake.

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

Feature | Nuclear Imaging | July 22, 2019 | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS
Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the de
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Videos | Nuclear Imaging | August 21, 2018
Rami Doukky, M.D., professor of medicine, preventive medicine and radiology, and chief of the Division of Cardiology
ASNC Announces Keynote Speakers for 2018 Annual Scientific Session
News | Nuclear Imaging | August 08, 2018
August 8, 2018 — The American Society of Nuclear Cardiology’s (ASNC) Annual Scientific Session, ASNC2018, will kick o
Overlay Init